Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.
about
Intravesical immunotherapy in nonmuscle invasive bladder cancerIntravesical chemotherapy in non-muscle-invasive bladder cancerApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyTargeting Hsp90 in urothelial carcinomaMycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment.Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder.A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancerAdvances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.Immunotherapy for bladder cancer.Bladder cancer: epidemiology, diagnosis, and management.Detection of bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma.Mycobacterial brain tuberculomas due to Bacille Calmette-Guérin intravesical chemotherapy for bladder cancer: A case report and literature review.The microbiome of the urinary tract--a role beyond infection.A cough conundrum in a patient with a previous history of BCG immunotherapy for bladder cancer.A Case of Acquired Rifampin Resistance in Mycobacterium Bovis Bacillus Calmette-Guérin-induced Cystitis: Necessity for Treatment GuidelinesGenomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations.Myobacterium bovis peri-prosthetic hip infection with successful prosthesis retention following intravesical BCG therapy for bladder carcinomaThe rationale for prophylactic cancer vaccines and need for a paradigm shift.Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancerMycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder CancerCD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer.Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC).Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.Haemophagocytic syndrome after intravesical bacille Calmette-Guérin instillation.Deconvolution of the Response to Bacillus Calmette-Guérin Reveals NF-κB-Induced Cytokines As Autocrine Mediators of Innate Immunity.Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer.Mycotic Aneurysm after Bacillus Calmette-Guérin Treatment: Case Report and Review of the Literature.Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladderThe efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation.Fever of unknown origin and pancytopenia caused by culture-proven delayed onset disseminated bacillus Calmette-Guerin (BCG) infection after intravesical instillation.Tuberculous Granuloma in the Scrotal Skin After Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer: A Case Report.A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection.Bacillus Calmette-Guérin immunotherapy: a rare cause for a ruptured common femoral artery.Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder.In vivo biodistribution and toxicity of intravesical administration of quantum dots for optical molecular imaging of bladder cancer.Histopathology of Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Immunotherapy for Urothelial Carcinoma.Disseminated infection due to Mycobacterium bovis after intravesical BCG instillation.Combined infection of vertebroplasty and aortic graft after intravesical BCG treatment.
P2860
Q26775979-52422728-E811-4CF5-8C5F-19673E561300Q26775982-1EF8CAAA-86AE-4A02-9CB4-49067538E2AFQ26798372-DE661264-747D-4E41-BBA5-EDDAB06A5234Q27023406-DDF1A720-A0FA-40C1-92D0-6B20D4192513Q27346705-789CA24A-D5FD-42F3-AFC6-0393EB6EF419Q33167629-9CB04FEE-1A9A-47B8-A759-604FDBB52051Q33780044-5F5E45D8-8902-49FA-BEC2-1645EA8B51F1Q33933049-79F1E2BF-FA7B-45AF-A0F1-AC863C056EBEQ34115106-B5EE31B0-B443-4AB8-B7B3-D754B9A10917Q34477444-9B326F60-15C6-4761-8ABF-2B370C21B512Q34983298-A20FF2D1-9B34-4B4D-8A12-7DCD7987C566Q35067132-975CB0C2-9E0E-4D02-887B-51C2484EE2DEQ35434020-7E43A3BF-7789-4E6E-8101-A3F4B1D8B678Q35544680-4229F65D-D646-478E-BC91-AD3874FC24ABQ35980116-831831C9-5896-450C-9AB2-048C6615277EQ36171212-1823A875-B2FE-4D2D-8177-CB6FD1460734Q36187495-E000C9ED-A129-44BF-B6FD-142982851D89Q36276438-B61660F7-5F87-49CA-9FC7-AC5738E5B3B9Q36423899-4E96F3DD-363B-450D-B161-CAAF6C837667Q36678207-6FF03DA7-BA04-463D-BE36-EE38B49E2DF1Q36839682-1D22FBE0-F288-4ED1-94DB-22ACBD7E1215Q36915014-241B1211-29BC-494D-B371-4ACD58D9A092Q37540079-F4E40F46-6C01-4C7E-A7B9-4E5B182AFFAFQ38091720-F765120C-FCFD-41E6-AE46-A074F0CA808BQ38144115-C4204F0F-F4D4-4627-881B-099380F2763EQ38656325-997251E2-112A-4FC0-A11D-9346E83C637BQ39021820-352EDC56-FAA8-4804-B80D-A45432E9E0B6Q39186574-E9801963-2542-4045-A903-32B15C009699Q39363055-4E78DB24-0B96-4E2C-B374-152338589493Q39702013-1C6B83DF-09AC-43EF-B5DA-092F9E3EBE31Q40043898-30108BE0-AF59-4007-AA58-17F90CC5910CQ40251491-6EB0D617-FBB2-4B60-A099-D67C7E10D3F6Q40373538-10D402FE-C89B-4E42-99A6-ABD25EBE4DEFQ40647471-92D9308E-C687-4972-AA44-1C0C3EEB954FQ40714176-6022480C-502A-4DDC-BB96-53A321B3B02DQ41238543-E3469963-A6EE-4634-9095-9CF15D4FE40DQ41518057-9EB43493-80EA-48C4-81D7-99D5E5CDD95FQ41525771-AFCEA172-81F1-4732-B5DA-01525AF5015AQ41852553-7AD67690-F2A3-4912-A1F9-93D7568348F0Q41971725-A00A4E84-CCB3-408E-A9D1-553B00C94B3A
P2860
Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Efficacy and safety of bacille ...... in superficial bladder cancer.
@ast
Efficacy and safety of bacille ...... in superficial bladder cancer.
@en
Efficacy and safety of bacille ...... in superficial bladder cancer.
@nl
type
label
Efficacy and safety of bacille ...... in superficial bladder cancer.
@ast
Efficacy and safety of bacille ...... in superficial bladder cancer.
@en
Efficacy and safety of bacille ...... in superficial bladder cancer.
@nl
prefLabel
Efficacy and safety of bacille ...... in superficial bladder cancer.
@ast
Efficacy and safety of bacille ...... in superficial bladder cancer.
@en
Efficacy and safety of bacille ...... in superficial bladder cancer.
@nl
P2860
P356
P1476
Efficacy and safety of bacille ...... in superficial bladder cancer.
@en
P2093
P2860
P304
P356
10.1086/314064
P407
P478
31 Suppl 3
P577
2000-09-01T00:00:00Z